Prevalence and Burden of Bronchiectasis in Tuberculous Patients

Pulmonary Tuberculoses Clinical Trial

Official title:

Prevalence and Burden of Bronchiectasis in Tuberculous Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04085133
• Other study ID #: 12345817
• Status: Completed
• Start date: September 26, 2019
• Est. completion date: April 1, 2020

Study information

• Verified date: September 2019
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Bronchiectasis was described in the early 19th century by Laennec. Bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree

Description:

Bronchiectasis was described in the early 19th century by Laennec. Bronchiectasis is a chronic condition characterized by permanent and irreversible dilatation of the bronchial airways and impairment of mucociliary transport mechanism due to repeated infection and inflammation leading to colonization of organism and pooling of the mucus in the bronchial tree. The prevalence of bronchiectasis is age-related and occurs in every age group and in the pre-antibiotic era . it most often began in childhood. Recent evidence shows that bronchiectasis disproportionately affects women and older individuals and will be contributing to increase in healthcare burden.[3] International data show an increase in the prevalence of bronchiectasis over recent years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: April 1, 2020
• Est. primary completion date: January 1, 2020
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• 1-patients were diagnosed to have tuberculosis by sputum culture and gene x pert. 2-patients were diagnosed to have bronchiectasis after lab and radiological examination as well as clinical score. 3- patients diagnosed as bronchiectasis after history of tuberculosis or anti Tuberculosis treatment with positive or negative tuberculous culture in the time of research.

Exclusion Criteria:

• 1-patients presented with other Pulmonary diseases. 2-Chronic liver and renal disease . 3- Lung cancer and tumors. 4- patients were previously diagnosed as bronchiectasis .

Related Conditions & MeSH terms

• Bronchiectasis
• Pulmonary Tuberculoses
• Tuberculosis
• Tuberculosis, Pulmonary

Intervention

Diagnostic Test:
• Gene Xpert Chest x ray and MSCT chest
Sputum sample for T.B will be done using gene expert device and chest xray and high resolution ct to evaluate bronchectasis

Locations

Country	Name	City	State
Egypt	Assiut unviresty	Assiut

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To study prevalence of bronchiectasis in TB patients by case per year.	How many patients of TB will be diagnosed as abronchiectasis	One year
Secondary	To evaluate the burden of bronchiectasis in TB patients	by frequency of need for hospital admission per year, need for outpatient clinical visits per month and frequency of need for antimicrobial therapy other than anti-tuberculous treatment per month	one year